Michael Cherny
Stock Analyst at Leerink Partners
(4.38)
# 338
Out of 5,135 analysts
114
Total ratings
60.92%
Success rate
15.42%
Average return
Main Sectors:
Stocks Rated by Michael Cherny
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MEDP Medpace Holdings | Maintains: Market Perform | $575 → $485 | $446.17 | +8.70% | 2 | Feb 11, 2026 | |
| CVS CVS Health | Maintains: Buy | $100 → $95 | $77.75 | +22.19% | 12 | Jan 27, 2026 | |
| MDLN Medline | Initiates: Outperform | $48 | $47.71 | +0.61% | 1 | Jan 12, 2026 | |
| CERT Certara | Upgrades: Outperform | $13 | $6.53 | +99.08% | 2 | Jan 6, 2026 | |
| DGX Quest Diagnostics | Maintains: Outperform | $203 → $210 | $204.39 | +2.74% | 3 | Oct 21, 2025 | |
| MCK McKesson | Maintains: Outperform | $785 → $850 | $946.97 | -10.24% | 15 | Sep 24, 2025 | |
| CAH Cardinal Health | Maintains: Outperform | $188 → $186 | $224.99 | -17.33% | 13 | Aug 12, 2025 | |
| PGNY Progyny | Upgrades: Outperform | $28 | $20.35 | +37.59% | 11 | Jul 8, 2025 | |
| BOLD Boundless Bio | Downgrades: Market Perform | $15 → $3 | $1.16 | +158.62% | 2 | May 28, 2025 | |
| NVST Envista Holdings | Maintains: Buy | $26 → $23 | $28.50 | -19.30% | 11 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $24 → $40 | $15.84 | +152.53% | 10 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $60 → $90 | $25.45 | +253.63% | 2 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $235 → $280 | $190.82 | +46.74% | 3 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $69 → $84 | $78.13 | +7.52% | 2 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $260 → $248 | $171.06 | +44.98% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $270 → $255 | $96.50 | +164.25% | 3 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $12.49 | - | 8 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $277 → $275 | $360.23 | -23.66% | 3 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $260 | $278.76 | -6.73% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8 | $2.38 | +236.13% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $17 | $4.66 | +264.81% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $113 → $53 | $1.64 | +3,111.01% | 2 | Jan 5, 2022 |
Medpace Holdings
Feb 11, 2026
Maintains: Market Perform
Price Target: $575 → $485
Current: $446.17
Upside: +8.70%
CVS Health
Jan 27, 2026
Maintains: Buy
Price Target: $100 → $95
Current: $77.75
Upside: +22.19%
Medline
Jan 12, 2026
Initiates: Outperform
Price Target: $48
Current: $47.71
Upside: +0.61%
Certara
Jan 6, 2026
Upgrades: Outperform
Price Target: $13
Current: $6.53
Upside: +99.08%
Quest Diagnostics
Oct 21, 2025
Maintains: Outperform
Price Target: $203 → $210
Current: $204.39
Upside: +2.74%
McKesson
Sep 24, 2025
Maintains: Outperform
Price Target: $785 → $850
Current: $946.97
Upside: -10.24%
Cardinal Health
Aug 12, 2025
Maintains: Outperform
Price Target: $188 → $186
Current: $224.99
Upside: -17.33%
Progyny
Jul 8, 2025
Upgrades: Outperform
Price Target: $28
Current: $20.35
Upside: +37.59%
Boundless Bio
May 28, 2025
Downgrades: Market Perform
Price Target: $15 → $3
Current: $1.16
Upside: +158.62%
Envista Holdings
Apr 29, 2025
Maintains: Buy
Price Target: $26 → $23
Current: $28.50
Upside: -19.30%
Feb 25, 2025
Maintains: Market Perform
Price Target: $24 → $40
Current: $15.84
Upside: +152.53%
Feb 7, 2025
Upgrades: Outperform
Price Target: $60 → $90
Current: $25.45
Upside: +253.63%
Jan 6, 2025
Upgrades: Outperform
Price Target: $235 → $280
Current: $190.82
Upside: +46.74%
Jan 6, 2025
Upgrades: Buy
Price Target: $69 → $84
Current: $78.13
Upside: +7.52%
Nov 19, 2024
Reiterates: Outperform
Price Target: $260 → $248
Current: $171.06
Upside: +44.98%
Nov 19, 2024
Reiterates: Outperform
Price Target: $270 → $255
Current: $96.50
Upside: +164.25%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $12.49
Upside: -
Oct 7, 2024
Maintains: Outperform
Price Target: $277 → $275
Current: $360.23
Upside: -23.66%
Feb 26, 2024
Initiates: Outperform
Price Target: $260
Current: $278.76
Upside: -6.73%
Feb 26, 2024
Initiates: Outperform
Price Target: $8
Current: $2.38
Upside: +236.13%
Feb 26, 2024
Initiates: Market Perform
Price Target: $17
Current: $4.66
Upside: +264.81%
Jan 5, 2022
Downgrades: Underperform
Price Target: $113 → $53
Current: $1.64
Upside: +3,111.01%